Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ZUXKG
ADC Name
F105-SSNPB-DM4
Synonyms
F105 SSNPB DM4
   Click to Show/Hide
Organization
Sanofi SA
Drug Status
Investigative
Indication
In total 3 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Melanoma [ICD11:2C30]
Investigative
Drug-to-Antibody Ratio
3-4
Antibody Name
F105
  Antibody Info 
Antigen Name
Integrin alpha-V (ITGAV)
  Antigen Info 
Payload Name
Mertansine DM4
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
N-sulfosuccinimidyl-4-(5-nitro-2 pyridyldithio) butyrate (SSNPB)
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 45.81
%
HT29 cells
Colon cancer
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 45.81% (Day 37) Positive ITGAV expression (ITGAV +++/++)
Method Description
Female athymic rats were inoculated with 5x106 HT29 cells subcutancously on the rear flank area. The animals were stratified into 13 groups, 6 animals per group based on a mean tumor volume for each group of approximately 250 mm3. On the day of grouping (day 7) each group received its initial dosing (175 ug/kg).
In Vivo Model HT-29 CDX model
In Vitro Model Colon cancer HT29 cells CVCL_A8EZ
References
Ref 1 Anti-integrin immunoconjugates, methods and uses; 2008-01-17.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.